Prima cleared to extend cancer trial to Korea
22 August, 2013 by Dylan Bushell-EmblingPrima BioMed (ASX:PRR) has received approval to extend its CANVAS cancer vaccine study to South Korea, the first Asian country to be involved in the phase II/III trial.
Ascend gears up for cancer immunotherapy trials
22 August, 2013 by Dylan Bushell-EmblingAscend Biopharmaceuticals CEO Clement Leong details the company’s plans for Australian clinical trials of its key products, a cancer vaccine and an oncolytic virus.
Sitting too much?
22 August, 2013Findings of the 12-year AusDiab follow-up study show that Australians aren’t making the lifestyle changes needed to address obesity, high blood pressure and diabetes.
Trials in autoimmune disease
21 August, 2013 by Susan WilliamsonGiving children their own cord blood to prevent them getting type 1 diabetes and development of a new immunotherapy are part of a more tailored approach to treating autoimmune diseases.
Innovation fund for health and medical research
20 August, 2013The Australian Government has committed to growing investment in the health and medical research sector with the Medical Research Innovation Fund.
Biotron develops capsule form of HIV/HCV drug
16 August, 2013 by Dylan Bushell-EmblingA trial of a capsule formulation of Biotron’s HIV/HCV drug candidate BIT225 has confirmed its ability to improve drug levels by around 160%.
Sirtex exceeds expectations with FY2013 profit
16 August, 2013The future looks bright for liver cancer treatment specialist Sirtex Medical (ASX: SRX), which has reported a net profit after tax of $18.3 million in FY13.
Positive results for patients in Patrys’s myeloma trial
15 August, 2013 by Dylan Bushell-EmblingTwo of the six multiple myeloma patients in the second and third cohorts of Patrys’s (ASX:PAB) phase I/IIa trial of PAT-SM6 have shown evidence of stable disease post-dosing.
Dendright and Janssen Biotech to collaborate on rheumatoid arthritis treatment
15 August, 2013Autoimmune therapy business Dendright has signed an agreement with Johnson & Johnson pharmaceutical company Janssen Biotech. The deal is an R&D collaboration and option to license agreement to develop and commercialise Dendright’s tolerising immunotherapy for the treatment of rheumatoid arthritis (RA).
Viralytics to get wider EU oncolytic virus patent
13 August, 2013 by Dylan Bushell-EmblingViralytics (ASX:VLA) will be granted a European patent covering a wider group of oncolytic viruses that bind to ICAM-1, target of the company’s Cavatak candidate.
Compumedics expects return to black for 1H14
13 August, 2013 by Dylan Bushell-EmblingCompumedics (ASX:CMP) expects to report a loss for FY13, but is projecting a return to profitability in 1H14 as it resolves its order-backlog issues.
QIMR changes its name
08 August, 2013In recognition of a large gift from a donor, QIMR will now be known as the QIMR Berghofer Medical Research Institute.
Patrys myeloma trial to move to final group
07 August, 2013 by Dylan Bushell-EmblingPatrys (ASX:PAB) has received safety board approval to move to the final group in its multidose escalation study of PAT-SM6 in multiple myeloma.
TGA miscounted clinical trial numbers
05 August, 2013 by Dylan Bushell-EmblingThe Therapeutic Goods Administration has upwardly revised its statistics on Australian clinical trial notifications from 2009-2012, after discovering errors in its earlier reports.
GTG raising up to $10.6m for BREVAGen expansion
01 August, 2013 by Dylan Bushell-EmblingGenetic Technologies (ASX:GTG) is conducting a capital raising worth up to $10.6m and will use the funds to expand its US market reach for breast cancer risk test BREVAGen.
